试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
编号:NCT05066230登记状态:提前终止企业 / 申办者:Kodiak Sciences Inc
药物 / 成分:KSI-301、Sham injection
登记的停止原因(原文):All patients completed the primary endpoint assessments. Additional follow-up after the primary endpoint was deemed not necessary by the Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
An Investigation of TAS-119 Monotherapy
编号:NCT02448589登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS-119
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
Management Of Pain After Cesarean Trial
编号:NCT03929640登记状态:提前终止企业 / 申办者:Milton S. Hershey Medical Center
药物 / 成分:Acetaminophen、Placebo、Ibuprofen
登记的停止原因(原文):Lead co-I left institution in 2020 and enrollment was suspended. Study was kept open in hopes of finding a replacement/meeting enrollment goal, but a new lead was not found. Study is now officially closed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
编号:NCT04267393登记状态:提前终止企业 / 申办者:Bristol-Myers Squibb
药物 / 成分:BMS-986263、Placebo
登记的停止原因(原文):Trial terminated because of lack of efficacy in the short term acute phase.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
编号:NCT04770246登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS-117、TAS-117、TAS-117、TAS-117
登记的停止原因(原文):The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
编号:NCT05346653登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:SGLT2i、No SGLT2i
登记的停止原因(原文):Enrollment goals were not met.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-04
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
编号:NCT05553392登记状态:提前终止企业 / 申办者:Stratpharma AG
药物 / 成分:StrataXRT、Aquaphor
登记的停止原因(原文):Protocol deviations and slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-03
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
编号:NCT03284723登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-06804103、PF-06804103 + Palbociclib +Letrozole
登记的停止原因(原文):The trial was terminated based on the stage in drug development and assessment of PF-06804103 relative to the leading external competition. The decision was not due to a safety concern.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
编号:NCT03530683登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Maplirpacept (PF-07901801)、Azacitidine、Venetoclax、Carfilzomib
登记的停止原因(原文):A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-03
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
编号:NCT03552380登记状态:提前终止企业 / 申办者:Roberto Pili
药物 / 成分:Entinostat、Nivolumab、Ipilimumab
登记的停止原因(原文):Funder halted development of compound in this disease
查看官方原始记录 ↗